Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease - PubMed (original) (raw)

. 2007 Apr 20;25(16):3080-4.

doi: 10.1016/j.vaccine.2007.01.022. Epub 2007 Jan 22.

Affiliations

• PMID: 17287053
• DOI: 10.1016/j.vaccine.2007.01.022

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

H Nøkleby et al. Vaccine. 2007.

Abstract

MenBvac is an OMV vaccine against systemic serogroup B Neisseria meningitidis disease. MenBvac was developed for control of a B:15:P1.7,16 subtype epidemic in Norway and administered to 180,000 subjects in 28 clinical studies. MeNZB, a daughter vaccine of MenBvac, was developed for a clonal B:4:P1.7b,4 epidemic in New Zealand and administered to 1 million people <20 years. The vaccines were similar regarding reactogenicity profile. Serious adverse events (SAEs) in general and particularly neurologic SAEs were very rare. Despite frequently reported local reactions and fever in those under 5 years, these OMV-based vaccines containing 25 microg antigen can be considered safe for use in all age groups.

PubMed Disclaimer

Comment in

Similar articles

• New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
  Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, Mulholland K, Martin D. Wong S, et al. Pediatr Infect Dis J. 2007 Apr;26(4):345-50. doi: 10.1097/01.inf.0000258697.05341.2c. Pediatr Infect Dis J. 2007. PMID: 17414400 Clinical Trial.
• MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
  Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. Oster P, et al. Vaccine. 2005 Mar 18;23(17-18):2191-6. doi: 10.1016/j.vaccine.2005.01.063. Vaccine. 2005. PMID: 15755593 Clinical Trial.
• Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
  Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. Holst J, et al. Vaccine. 2009 Jun 24;27 Suppl 2:B3-12. doi: 10.1016/j.vaccine.2009.04.071. Epub 2009 May 28. Vaccine. 2009. PMID: 19481313 Review.
• Recent developments in vaccines to prevent meningococcal serogroup B infections.
  Vermont CL, van den Dobbelsteen GP, de Groot R. Vermont CL, et al. Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Curr Opin Mol Ther. 2003. PMID: 12669468 Review.

Cited by

• Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.
  Moodley C, du Plessis M, Ndlangisa K, de Gouveia L, Klugman KP, von Gottberg A; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Moodley C, et al. J Clin Microbiol. 2012 Nov;50(11):3678-86. doi: 10.1128/JCM.01079-12. Epub 2012 Sep 12. J Clin Microbiol. 2012. PMID: 22972827 Free PMC article.
• Isolation Method and Characterization of Outer Membranes Vesicles of Helicobacter pylori Grown in a Chemically Defined Medium.
  Melo J, Pinto V, Fernandes T, Malheiro AR, Osório H, Figueiredo C, Leite M. Melo J, et al. Front Microbiol. 2021 Jun 2;12:654193. doi: 10.3389/fmicb.2021.654193. eCollection 2021. Front Microbiol. 2021. PMID: 34149641 Free PMC article.
• Expression, purification and preliminary X-ray analysis of the Neisseria meningitidis outer membrane protein PorB.
  Tanabe M, Iverson TM. Tanabe M, et al. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Oct 1;65(Pt 10):996-1000. doi: 10.1107/S1744309109032333. Epub 2009 Sep 23. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009. PMID: 19851005 Free PMC article.
• Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.
  Klein Klouwenberg P, Bont L. Klein Klouwenberg P, et al. Clin Dev Immunol. 2008;2008:628963. doi: 10.1155/2008/628963. Clin Dev Immunol. 2008. PMID: 18825269 Free PMC article. Review.
• Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response.
  Kim OY, Park HT, Dinh NTH, Choi SJ, Lee J, Kim JH, Lee SW, Gho YS. Kim OY, et al. Nat Commun. 2017 Sep 20;8(1):626. doi: 10.1038/s41467-017-00729-8. Nat Commun. 2017. PMID: 28931823 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information